TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32910476
Drug: Interaction between
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interaction between treatment arms
Study: 35260570
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a RAC1/RAC3 dual-target inhibitor and cetuximab
Study: 33305109
Drug: Etelcalcetide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide + oral calcium preparation (group E+Ca)
Study: 35367787
Drug: Metronomic adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic adjuvant chemotherapy (MAC) consisting of weekly oral methotrexate (15 mg/m²) and celecoxib (200 mg orally twice daily) for 6 months
Study: 32222134
Drug: Vericiguat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat (10 mg once daily)
Study: 35977769
Drug: Diazoxide 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide 5 mg/kg orally loading dose, then 1.5 mg/kg every 12 hours maintenance dose, titrated to target BGC 2.6‐5.4 mmol/L
Study: 34342893
Drug: Gel nail
Normalized name: urea Topical Gel [Kera Nail]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel nail polish application
Study: 33932093
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of apremilast at 20, 30, or 40 mg
Study: 33932093
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of apremilast at 30 mg b.i.d. for 14 days
Study: 32876689
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone (n=76)
Study: 32548811
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of ascites, ALBI grade 2–3, serum ɑ-fetoprotein level ≥ 400 ng/mL, total tumor volume ≥ 396 cm3, presence of vascular invasion, poor performance status
Study: 34263472
Drug: Edasalonexent softgel
Normalized name: Edasalonexent
DrugBank: Edasalonexent (DB15010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edasalonexent softgel capsules (100 mg or 250 mg)
Study: 36103415
Drug: Aggressive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive fluid resuscitation (20 ml/kg bolus, followed by 3 ml/kg/hour)
Study: 36103415
Drug: Moderate fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate fluid resuscitation (10 ml/kg bolus for hypovolemia or no bolus for normovolemia, followed by 1.5 ml/kg/hour)
Study: 35751772
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose tranexamic acid (TXA): 50 mg/kg, 5 mg/kg/hr
Study: 36126603
Drug: Personalized swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized swallowing rehabilitation twice a day for 10 days
Study: 36078233
Drug: β‐endorphin levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐endorphin levels before chemotherapy
Study: 36078233
Drug: β‐endorphin levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐endorphin levels after chemotherapy
Study: 36078233
Drug: Serotonin levels
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin levels before chemotherapy
Study: 34645654
Drug: SPACE intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPACE intervention (automated search, pharmacist outreach, patient invitation for medication review)
Study: 32557260
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate hydrate (ZAH; zinc, 50 mg/day)
Study: 32557260
Drug: Polaprezinc (PPZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc (PPZ; zinc, 34 mg/day)
Study: 32557260
Drug: Pre-dialysis SCre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-dialysis SCre level ≥ 10.0 mg/dL
Study: 35637624
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg CBD
Study: 32729120
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg CBD
Study: 35697050
Drug: SARS-CoV-2 recombinant
Normalized name: SARS-CoV-2 recombinant spike protein antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 recombinant protein vaccine (high dose)
Study: 34332895
Drug: Topical lotilaner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lotilaner ophthalmic solution, 0.25%
Study: 34668065
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Otosporin®
Study: 34420980
Drug: Eteplirsen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eteplirsen treatment
Study: 32220414
Drug: Buprenorphine initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine initiation (8 mg sublingual buprenorphine or 8-2 mg sublingual buprenorphine/naloxone)
Study: 34578900
Drug: High Protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Protein (HP) toddler milk formula (30 g protein, 10 g fat)
Study: 34578900
Drug: Low Protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Protein (LP) toddler milk formula (7 g protein, 20 g fat)
Study: 33023997
Drug: Respiratory therapist‐driven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory therapist‐driven oxygen titration after an electronic alert
Study: 33023997
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (titration based on physician order)
Study: 33057314
Drug: IV1 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV1 (single intravenous dose of 15 mg TXA/kg prior to skin incision)
Study: 33408009
Drug: IV2 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV2 (two intravenous doses of 15 mg TXA/kg: one prior to skin incision and one 6 hours after)
Study: 33408009
Drug: TOP (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOP (2 g TXA in 50 ml of saline irrigated topically at the end of surgery)
Study: 36123259
Drug: 20 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU/kg Omtv + vaccine
Study: 36123259
Drug: 40 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU/kg Omtv + vaccine
Study: 36123259
Drug: 20 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU/kg HRIG + vaccine
Study: 35570983
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + vaccine
Study: 35604745
Drug: Marriage checkup
Normalized name: Cardui Mariae Fructus
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marriage checkup (active treatment)
Study: 33536102
Drug: L-carnitine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (50 mg/kg/day)
Study: 32871923
Drug: Hudi enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hudi enteric-coated capsules (HEC)
Study: 32871923
Drug: Enteric-coated mesalazine
Normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mesalazine tablets placebo
Study: 33557762
Drug: Individualized protocol
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized protocol (IP) group - individualized rescue morphine dosing based on fentanyl test results (10 μg/kg if positive, 50 μg/kg if negative)
Study: 33557762
Drug: Conservative protocol
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative protocol (CP) group - fixed rescue morphine dosing (25 μg/kg)
Study: 33119047
Drug: ω-3 fatty
Normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 fatty acids, 1 g per day
Study: 35131155
Drug: Self-Monitored Blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Monitored Blood Glucose (BGM) (4 times daily)
Study: 35258101
Drug: Vericiguat 2.5
Normalized name: vericiguat 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 2.5 mg (up-titrated to 5 mg and 10 mg) + nitroglycerin 0.4 mg sublingual
Study: 35258101
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + nitroglycerin 0.4 mg sublingual
Study: 35780177
Drug: Cold plasma
Normalized name: TITANIUM DIOXIDE 1.26 g in 30 g TOPICAL CREAM [Cold Plasma Plus Neck and Chest SPF25]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold plasma treatment combined with pyroligneous acid
Study: 35780177
Drug: Cold plasma
Normalized name: TITANIUM DIOXIDE 1.26 g in 30 g TOPICAL CREAM [Cold Plasma Plus Neck and Chest SPF25]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold plasma treatment
Study: 35780177
Drug: Seed plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seed plasma treatment combined with biochar application
Study: 35780177
Drug: Seed plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seed plasma treatment with biochar
Study: 33516285
Drug: Lumacaftor 200
Normalized name: lumacaftor 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor 200 mg–ivacaftor 250 mg orally once every 12 h for up to 120 weeks
Study: 33516285
Drug: Lumacaftor–ivacaftor therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor–ivacaftor therapy
Study: 38741174
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplements (MMS)
Study: 32859250
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with oral medication
Study: 32859250
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment plan
Study: 34376972
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.0 mg/kg bolus, 1.0 mg/kg/h until end of surgery)
Study: 36299194
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (experimental group)
Study: 39606414
Drug: Neoadjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant androgen deprivation therapy (NADT)
Study: 36005919
Drug: Dry Cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Cupping Therapy (DCT)
Study: 36005919
Drug: Creatine Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine Supplementation + Dry Cupping Therapy (CS+DCT)
Study: 34734875
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (from RCTs)
Study: 35027421
Drug: Corticocortical paired
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticocortical paired associative stimulation (ccPAS) in conjunction with conventional rehabilitation treatment, 10 interventions, 5 times a week for 2 weeks.
Study: 35027421
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation treatment with sham stimulation.
Study: 35027421
Drug: Corticocortical paired
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticocortical paired associative stimulation (ccPAS) in conjunction with conventional rehabilitation treatment.
Study: 33142485
Drug: 5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/kg star anise
Study: 33142485
Drug: 0.22 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.22 g/kg essential oil
Study: 33142485
Drug: 5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/kg leavings
Study: 34060731
Drug: Pycnogenol® (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol® (150 mg daily in 3 doses of 50 mg)
Study: 33575976
Drug: Self-assessed activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-assessed activities of daily living
Study: 33575976
Drug: Research assistant-assessed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Research assistant-assessed activities of daily living
Study: 33575976
Drug: Self-assessed instrumental
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-assessed instrumental activities of daily living
Study: 33575976
Drug: Research assistant-assessed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Research assistant-assessed instrumental activities of daily living
Study: 34893371
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (TA) using an eutectic mixture of lidocaine and prilocaine (EMLA)
Study: 32656729
Drug: Liraglutide (subcutaneous)
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide (subcutaneous) 0.6 mg/day to 3.0 mg
Study: 32656729
Drug: Liraglutide (subcutaneous)
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide (subcutaneous)
Study: 36303593
Drug: NET Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: NET Device (active treatment)
Study: 32575611
Drug: Flaxseed lignan
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed lignan extract (50 mg/day secoisolariciresinol diglucoside)
Study: 32575611
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Flaxseed lignan and Placebo)
Study: 35502668
Drug: Oliceridine injection
Normalized name: oliceridine Injection
DrugBank: Oliceridine (DB14881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oliceridine injection
Study: 33831552
Drug: Exenatide twice
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide twice a day plus glargine
Study: 33831552
Drug: Aspart 70/30
Normalized name: INSULIN,ASPART 70/30 NOVOLOG FLEXPEN 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspart 70/30 twice a day
Study: 32242395
Drug: Western Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western Medicine (cetirizine hydrochloride, vitamin C, and vitamin B complex)
Study: 34807286
Drug: Transurethral cystolitholapaxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral cystolitholapaxy plus medical therapy (tamsulosin plus finasteride)
Study: 32247061
Drug: Elective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective treatment
Study: 32763021
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (remifentanil infused to a target plasma concentration of 1.7 ng/mL)
Study: 33600538
Drug: Conus interface
Normalized name: Blitum bonus-henricus pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conus interface implants
Study: 33600538
Drug: Flat-to-flat interface
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flat-to-flat interface implants
Study: 33600538
Drug: Platform-switched interface
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switched interface implants
Study: 32515058
Drug: Befriending Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befriending Therapy (BT)
Study: 35413932
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of umbilical cord-derived Wharton’s jelly mesenchymal stromal cells (WJ-MSCs)
Study: 35413932
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of umbilical cord-derived Wharton’s jelly mesenchymal stromal cells (WJ-MSCs)
Study: 35765084
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy (30-min Armguider robot-assisted therapy, 5 days a week for 6 weeks)
Study: 35765084
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (6 weeks)
Study: 32278266
Drug: Off-label prescription
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-label prescription after 2018
Study: 32278266
Drug: Under indication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Under indication prescription
Study: 32264949
Drug: Non‐patch group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐patch group
Study: 34550862
Drug: Sound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sound therapy (ST) with virtual reality (VR) stimuli
Study: 34550862
Drug: Sound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sound therapy (ST) alone
Study: 35835265
Drug: Investigational regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational regimen to increase and maintain plasma potassium (p-K) at high-normal levels (4.5-5.0 mmol/l)
Study: 33736617
Drug: Group meta-cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group meta-cognitive therapy
Study: 35021194
Drug: Green-MED diet
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green-MED diet (Mankai 100 g/d, green tea 3-4 cups/d, +800 mg/d polyphenols)
Study: 35021194
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet (MED) (28 g walnuts/d, +440 mg/d polyphenols)
Study: 33226139
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks for 52 weeks (Arm A)
Study: 33226139
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks for 24 weeks, followed by every 4 weeks for 28 weeks (Arm B)
Study: 36498758
Drug: Fu's subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fu's subcutaneous needling (FSN)
Study: 32005340
Drug: 8-week internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week internet-based cognitive behavioral therapy (CBT)
Study: 33957937
Drug: Robotic-therapy Group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-therapy Group (RG) - 20 sessions of 45 min each, five days a week for four weeks
Study: 33957937
Drug: Robotic-therapy Group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-therapy Group (RG)
Study: 33771278
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of standardized outpatient treatment (cognitive behavioral therapy)
Study: 33771278
Drug: 16 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 weeks of standardized outpatient treatment (cognitive behavioral therapy)
Study: 33771278
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of treatment (regardless of group assignment)
Study: 36184583
Drug: Modified application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified application of COOK Cervical Ripening Balloon (CCRB) with uterine balloon filled to 120 mL and vaginal balloon filled to 40 mL, with light traction applied and removed after 12 hours.
Study: 32444264
Drug: Pharmacologic prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic prophylaxis (subcutaneous heparin) plus routine care
Study: 35861861
Drug: CT-guided external
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided external beam radiation therapy (EBRT)
Study: 33215284
Drug: No levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: No levodopa treatment strategies
Study: 33215284
Drug: Levodopa with
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa with other medications
Study: 35075087
Drug: Kinesio Taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio Taping (KT) in combination with standard rehabilitation protocol
Study: 34129953
Drug: Gamification intervention
Normalized name: Gamifant
DrugBank: Emapalumab (DB14724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gamification intervention with social incentives (participants receive a Fitbit Inspire 2 and select a daily step goal, enrolled in a game with loss-framed points and levels)
Study: 34129953
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (participants receive a Fitbit Inspire 2 and select a daily step goal without gamification)
Study: 34802002
Drug: UControlDrink smartphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: UControlDrink smartphone app (UCD) with treatment as usual (TAU)
Study: 34640468
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction (MBSR) group therapy
Study: 35927828
Drug: Syrup placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup placebo
Study: 32819681
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol (up to 15 mg) before primary percutaneous coronary intervention
Study: 32819681
Drug: Conventional STEMI
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional STEMI therapy
Study: 32819681
Drug: Early intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intravenous metoprolol in patients with GLS ≥ -11.5%
Study: 35620570
Drug: empagliflozin‐metformin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin‐metformin combination (25 mg and 2000 mg daily)
Study: 32277872
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules taken orally once a day for 8 weeks)
Study: 32286644
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy (valganciclovir, 900 mg, twice daily until 2 consecutive negative tests a week apart for 100 days)
Study: 32426316
Drug: Individualized nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized nutrition prescription (INP)
Study: 35838438
Drug: Ketamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine treatment in clinical trials (exact dosage and duration not specified)